Prelude Therapeutics Inc (PRLD)

10:53 AM

PRLD Initiates Coverage On Prelude Therapeutics -- Price Target Announced at $9.00 - GuruFocus

10:53 AM

May 03, 2026

Prelude Therapeutics (PRLD) price target increased by 19.35% to 6.29 - MSN

May 03, 2026

May 01, 2026

Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer - Yahoo Finance

May 01, 2026

Apr 30, 2026

Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research - MarketBeat

Apr 30, 2026

Apr 29, 2026

Prelude Therapeutics (NASDAQ: PRLD) outlines 2026 proxy votes on directors, pay and auditor - Stock Titan

Apr 29, 2026

Apr 29, 2026

Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Decreases By 22.1% - MarketBeat

Apr 29, 2026

Apr 29, 2026

HC Wainwright Issues Positive Estimate for PRLD Earnings - MarketBeat

Apr 29, 2026

Apr 28, 2026

RA Capital reports 7.88M-share Prelude Therapeutics (PRLD) stake - Stock Titan

Apr 28, 2026

Apr 28, 2026

Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

Apr 28, 2026

Apr 28, 2026

H.C. Wainwright raises Prelude Therapeutics price target to $8 By Investing.com - Investing.com Canada

Apr 28, 2026

Apr 27, 2026

PRLD Maintained by HC Wainwright & Co. -- Price Target Raised to $8 - GuruFocus

Apr 27, 2026

Apr 27, 2026

HC Wainwright Issues Positive Forecast for Prelude Therapeutics (NASDAQ:PRLD) Stock Price - MarketBeat

Apr 27, 2026

Apr 23, 2026

Prelude Therapeutics (NASDAQ:PRLD) Director David Bonita Buys 2,815,315 Shares - MarketBeat

Apr 23, 2026

Apr 23, 2026

Prelude Therapeutics (NASDAQ:PRLD) Director Buys $12,499,998.60 in Stock - MarketBeat

Apr 23, 2026

Apr 23, 2026

Insider Purchase: Director at $PRLD Buys 1,689,189 Shares - Moomoo

Apr 23, 2026

Apr 23, 2026

Orbimed entities acquire $12.5m in Prelude Therapeutics stock By Investing.com - Investing.com Canada

Apr 23, 2026

Apr 23, 2026

Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock - Investing.com

Apr 23, 2026

Apr 23, 2026

Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock By Investing.com - Investing.com South Africa

Apr 23, 2026

Apr 23, 2026

Orbimed entities acquire $12.5m in Prelude Therapeutics stock - Investing.com

Apr 23, 2026

Apr 23, 2026

OrbiMed funds add Prelude Therapeutics (PRLD) shares at $4.44 in offering - Stock Titan

Apr 23, 2026

Apr 23, 2026

OrbiMed funds boost Prelude Therapeutics (NASDAQ: PRLD) stake with 2.82M-share buy - Stock Titan

Apr 23, 2026

Apr 21, 2026

Prelude Therapeutics Enters Underwriting for $85.5 Million Equity Offering Led by RA Capital - TradingView

Apr 21, 2026

Apr 20, 2026

Prelude Therapeutics (PRLD) Unveils Promising Preclinical Data f - GuruFocus

Apr 20, 2026

Apr 20, 2026

Prelude Therapeutics (PRLD) Launches $90M Public Offering with S - GuruFocus

Apr 20, 2026

Apr 20, 2026

Prelude Therapeutics Shares Rise on Positive Preclinical Data for Breast Cancer Drug - Moomoo

Apr 20, 2026

Apr 20, 2026

Prelude Therapeutics Unveils Promising Preclinical Data for First-in-Class Oral KAT6A Degrader PRT13722 in HR+/HER2- Breast Cancer at AACR 2026 12 - Minichart

Apr 20, 2026

Apr 20, 2026

Prelude Therapeutics prices $90M equity offering - MSN

Apr 20, 2026

Apr 20, 2026

Prelude Therapeutics prices $90M stock offering at $4.44/share By Investing.com - Investing.com Canada

Apr 20, 2026

Apr 20, 2026

Prelude Therapeutics presents preclinical data on breast cancer drug By Investing.com - Investing.com Canada

Apr 20, 2026

Apr 20, 2026

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering - ChartMill

Apr 20, 2026

Apr 20, 2026

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 - Yahoo Finance

Apr 20, 2026

Apr 15, 2026

Prelude Therapeutics names Charles Morris as chief medical officer By Investing.com - Investing.com Australia

Apr 15, 2026

Apr 15, 2026

Prelude Therapeutics Appoints Dr. Charles Morris as Chief Medical Officer to Advance Precision Oncology Pipeline - Minichart

Apr 15, 2026

Apr 15, 2026

Prelude Therapeutics (PRLD) Appoints New Chief Medical Officer - GuruFocus

Apr 15, 2026

Apr 15, 2026

Prelude Therapeutics Appoints Veteran Oncologist as New CMO - TipRanks

Apr 15, 2026

Apr 15, 2026

Prelude Therapeutics names Charles Morris as chief medical officer - Investing.com

Apr 15, 2026

Apr 15, 2026

Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer - The Manila Times

Apr 15, 2026

Apr 15, 2026

New CMO joins Prelude Therapeutics (NASDAQ: PRLD) as pipeline advances - Stock Titan

Apr 15, 2026

Apr 13, 2026

Bull Bear: Is Prelude Therapeutics Incorporated stock a good pick for beginners2026 Stock Rankings & Capital Efficiency Focused Ideas - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Activity Recap: Whats the beta of Prelude Therapeutics Incorporated stockQuarterly Trade Report & Safe Capital Investment Plans - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

Aug Swings: What is the Moat Score of Prelude Therapeutics Incorporated2026 Earnings Impact & Weekly Stock Breakout Alerts - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

Prelude Therapeutics (NASDAQ:PRLD) Shares Up 4.3%Still a Buy? - MarketBeat

Apr 10, 2026

Apr 09, 2026

Retail Surge: Is Prelude Therapeutics Incorporated a turnaround story2026 Drop Watch & Consistent Income Trade Recommendations - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

PRLD Technical Analysis | Trend, Signals & Chart Patterns | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill

Apr 08, 2026

Apr 07, 2026

Loss Report: How do insiders feel about Prelude Therapeutics IncorporatedExit Point & Scalable Portfolio Growth Methods - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

IPO Launch: Will Prelude Therapeutics Incorporated stock go up in YEARMarket Performance Recap & Safe Capital Growth Trade Ideas - baoquankhu1.vn

Apr 06, 2026

Apr 03, 2026

Is Prelude (PRLD) Stock Declining | Price at $4.08, Down 7.27%Continuation Signals - Newser

Apr 03, 2026

Apr 02, 2026

Prelude Therapeutics Incorporated (PRLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Apr 02, 2026

Apr 01, 2026

Prelude Therapeutics reports 2025 results and advances oncology pipeline - MSN

Apr 01, 2026

Mar 31, 2026

PRLD Technical Analysis & Stock Price Forecast - Intellectia AI

Mar 31, 2026